Morning vs. afternoon: can timing boost cancer immunotherapy?

NCT ID NCT07405086

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 160 adults with several cancer types will be randomly assigned to morning or afternoon treatment, and the team will track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

immune checkpoint inhibitor

What this could lead to

If timing matters, this could help doctors schedule immunotherapy to improve its effectiveness against several types of advanced cancer.

What could go wrong

This is an early-phase study on timing, not a new drug. The effect may be small or absent, and results may not apply to all cancer types.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cancer cutaneous melanoma head and neck squamous cell carcinoma hepatocellular carcinoma lung cancer lung neoplasm melanoma metastatic malignant neoplasm metastatic melanoma Neoplasm Metastasis non-small cell lung carcinoma renal cell adenocarcinoma renal cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • OHSU Knight Cancer Institute

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact